Publications
Selected Publications
- The duality of STAT2 mediated type I interferon signaling in the tumor microenvironment and chemoresistance.
Canar J, Darling K, Dadey R, Gamero AM.Cytokine. 2023 Jan;161:156081. doi: 10.1016/j.cyto.2022.156081. Epub 2022 Oct 31.PMID: 36327541
- Exposing the Two Contrasting Faces of STAT2 in Inflammation.
Duodu P, Sosa G, Canar J, Chhugani O, Gamero AM.J Interferon Cytokine Res. 2022 Sep;42(9):467-481. doi: 10.1089/jir.2022.0117. Epub 2022 Jul 25.PMID: 35877097
- Targeted Stat2 deletion in conventional dendritic cells impairs CTL responses but does not affect antibody production.
Qiu CC, Kotredes KP, Cremers T, Patel S, Afanassiev A, Slifker M, Gallucci S, Gamero AM.
Oncoimmunology. 2020 Dec 29;10(1):1860477. doi: 10.1080/2162402X.2020.1860477. PMID: 33457079; PMCID: PMC7781843.
- STAT2 dependent Type I Interferon response promotes dysbiosis and luminal expansion of the enteric pathogen Salmonella Typhimurium.
Wilson RP, Tursi SA, Rapsinski GJ, Medeiros NJ, Le LS, Kotredes KP, Patel S, Liverani E, Sun S, Zhu W, Kilpatrick L, Winter SE, Gamero AM, Tükel Ç.
PLoS Pathog. 2019 Apr 22;15(4):e1007745. doi: 10.1371/journal.ppat.1007745. PMID: 31009517; PMCID: PMC6513112.
- Host STAT2/type I interferon axis controls tumor growth.
Yue C, Xu J, Tan Estioko MD, Kotredes KP, Lopez-Otalora Y, Hilliard BA, Baker DP, Gallucci S, Gamero AM.
Int J Cancer. 2015 Jan 1;136(1):117-26. doi: 10.1002/ijc.29004. Epub 2014 Jun 17. PMID: 24895110; PMCID: PMC4199898.
- STAT2 contributes to promotion of colorectal and skin carcinogenesis.
Gamero AM, Young MR, Mentor-Marcel R, Bobe G, Scarzello AJ, Wise J, Colburn NH
Cancer
Prev Res (Phila). 2010 Apr;3(4):495-504. doi: 10.1158/1940-6207.CAPR-09-0105. Epub 2010 Mar 16. PMID: 20233899; PMCID: PMC2851485.